Vaxxinity, Inc.
🇺🇸United States
AC Immune's ACI-7104 Shows Promise in Phase II Parkinson's Disease Trial
AC Immune's stock surged by over 20% following positive interim data from its Phase II VacSYn trial of ACI-7104.056 for Parkinson's disease.
AC Immune's stock surged by over 20% following positive interim data from its Phase II VacSYn trial of ACI-7104.056 for Parkinson's disease.